Common birth control shot linked to risk of HIV infection

January 4, 2018, The Endocrine Society
Zdenek Hel. Credit: UAB

Transitioning away from a popular contraceptive shot known as DMPA could help protect women in Sub-Saharan Africa and other high-risk regions from becoming infected with HIV, according to a research review published in the Endocrine Society's journal Endocrine Reviews.

The predominant contraceptive in Sub-Saharan Africa is depot-medroxyprogesterone acetate (DMPA)—a shot administered every three months. Human studies suggest DMPA use may raise the risk of HIV infection by 40 percent. Other forms of contraceptive shots do not show the same correlation with HIV infection. In this article, the authors review the underlying biological mechanisms that could contribute to increased risk of HIV infection for certain hormonal contraceptives but not others.

According to UNAIDS, 36.7 million people worldwide were living with HIV as of 2016. AIDS is the most advanced stage of HIV infection.

"To protect individual and public health, it is important to ensure women in areas with high rates of HIV infection have access to affordable contraceptive options," said the review's first author, Prof. Janet P. Hapgood, Ph.D., of the University of Cape Town in Cape Town, South Africa. "Increasing availability of contraceptives that use a different form of the female hormone progestin than the one found in DMPA could help reduce the risk of HIV transmission."

In addition to these clinical studies, the review's authors examined animal, cell and biochemical research on the form of progestin used in DMPA—medroxprogesterone acetate, or MPA. The analysis revealed MPA acts differently than other forms of progestin used in contraceptives. MPA behaves like the in the cells of the that can come in contact with HIV.

"The increased rate of HIV infection among women using DMPA contraceptive shots is likely due to multiple reasons, including decreases in immune function and the protective barrier function of the female genital tract," Hapgood said. "Studying the biology of MPA helps us understand what may be driving the increased rate of HIV infection seen in human research. These findings suggest other forms of birth control should rapidly replace DMPA shots."

Explore further: Risk of HIV infection in studies of African women using hormonal contraceptives

More information: Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms, Endocrine Reviews, academic.oup.com/edrv/advance- … r.2017-00103/4788769

Related Stories

Risk of HIV infection in studies of African women using hormonal contraceptives

January 22, 2015
Use of the injectable progestin contraceptive depot-medroxyprogesterone acetate (DMPA) is linked to an increased risk for HIV infection, according to an article published by Charles Morrison of FHI 360 and colleagues in this ...

Why do certain hormonal contraceptives increase the risk of HIV?

September 1, 2015
In recent years, evidence has been building that injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera or DMPA) is associated with an increased risk of HIV infection. Now a study published in the September ...

Study finds link between injectable contraceptives and breast cancer risk in younger women

April 4, 2012
The first large-scale U.S.-based study to evaluate the link between an injectable form of progestin-only birth control and breast cancer risk in young women has found that recent use of a year or more doubles the risk. The ...

Study supports link between injectable hormonal contraceptive and HIV risk

January 9, 2015
Women using depot medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera or the birth control shot, have a moderately increased risk of becoming infected with HIV, a large meta-analysis of 12 studies involving ...

Long-term use of certain contraception injections associated with increased fracture risk

May 6, 2010
A new study presented today at the World Congress on Osteoporosis (IOF WCO-ECCEO10) in Florence, Italy shows that DMPA, a commonly used injectible contraceptive, is associated with higher risk of bone fracture when used alone, ...

Injectable progesterone contraceptives may be associated with poor periodontal health

February 6, 2012
Injectable progesterone contraceptives may be associated with poor periodontal health, according to research in the Journal of Periodontology. The study found that women who are currently taking depotmedroxyprogesterone acetate ...

Recommended for you

Overweight or smoking mums cause 'worrying changes' to unborn children's thyroid

October 23, 2018
Smoking or being overweight during pregnancy causes 'worrying changes' to the development of the unborn baby's thyroids, and could predispose them to disease after birth, according to a new study from the University of Aberdeen.

Why mothers in mainland China, Hong Kong and Taiwan choose cesarean delivery

October 16, 2018
Pregnant women in mainland China, Hong Kong, and Taiwan are more likely to express preference for cesarean section (CS) as their mode of delivery later in pregnancy and postpartum, as compared to early in pregnancy, according ...

Importance of cell cycle and cellular senescence in the placenta discovered

October 15, 2018
Working with researchers from Stanford University and St. Anna Children's Cancer Research, researchers from Jürgen Pollheimer's laboratory at the Medical University of Vienna's Department of Obstetrics and Gynecology have ...

C-section rates have nearly doubled since 2000: study

October 12, 2018
(HealthDay)—The number of women delivering babies via cesarean section has nearly doubled worldwide since 2000, to about 21 percent, new research shows.

Study of nearly 41,000 women who almost died giving birth shows who's most at risk

October 10, 2018
Tens of thousands of American women each year need emergency treatment to save their lives while they deliver their babies, or immediately after. A new study shows how much their risk of a life-threatening birth depends on ...

Long-acting injectable implant shows promise for HIV treatment and prevention

October 9, 2018
A persistent challenge in HIV/AIDS treatment and prevention is medication adherence – getting patients to take their medication as required to get the best results.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.